In the paper titled “Sarcoma Immunotherapy: Past Approaches and Future Directions” in the following sentence: “Currently, there is a phase II trial of a trivalent peptide vaccine to the gangliosides GD2, GD3, and GM2 in patients with sarcoma that have had solitary metastases excised (NCT00597272),” the corrected identifier should be NCT01141491.
Corrigendum | Open Access
Corrigendum to “Sarcoma Immunotherapy: Past Approaches and Future Directions”
Received21 May 2015
Accepted27 May 2015
Published09 Jun 2015
Copyright
Copyright © 2015 S. P. D’Angelo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.